The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis
Lab / animal
OA: green
CC0
⤵ 20 in-corpus citations
AI-generated summary
This in vitro study investigated associations between progestin treatment, nuclear receptor protein expression, and inflammatory cytokine mRNA levels in endometriotic stromal cells.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Endometriosis is an inflammatory disease and nuclear receptors play a crucial role in mediating the inflammatory response. In endometrial stromal cells (ESC), nuclear receptors expression can be influenced by the local environment. Progestins are first-line, on-label treatments of endometriosis that may have direct effects on endometriotic lesions through these nuclear receptors. Therefore, we investigated whether there was an association between nuclear receptors expression and the influence of progestins on inflammatory cytokines production in a preliminary, in vitro study with primary cultures. ESC from endometrial biopsies of six subjects with histologically confirmed endometriosis were treated for 6 h with medium alone or with TNF-α (10 or 100 ng/ml) in the presence of dienogest (DNG), medroxyprogesterone acetate (MPA) and norethisterone acetate (NETA) 10-5 M. The progestin-mediated change in IL6, IL8 and MCP-1 mRNA transcription was measured, as was the PRA, PRB, GR, AR and MCR protein expression. The change (medium versus TNF-α 10 ng/ml and medium versus TNF-α 100 ng/ml) in IL6 mRNA transcription was positively associated with the change in PRB, but not PRA with both DNG and NETA treatment. The change in IL8 mRNA was negatively associated with AR expression in the presence of NETA. The change in MCP-1 mRNA expression was positively associated with GR expression and negatively associated with MCR after MPA treatment. The associations between the change in cytokines mRNA expression and nuclear receptors protein expression in response to progestins activity may indirectly suggest different activities of these compounds at a local level worthy of further investigations.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (14)
- Classification and pharmacology of progestins via openalex
- Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment via openalex
- Does dienogest influence the inflammatory response of endometriotic cells? A systematic review via openalex
- Dominant expression of progesterone receptor form B mRNA in ovarian endometriosis via openalex
- Drospirenone induces decidualization in human eutopic endometrial stromal cells and reduces DNA synthesis of human endometriotic stromal cells via openalex
- Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis via openalex
- Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics via openalex
- Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study via openalex
- Progesterone receptor isoform A but not B is expressed in endometriosis via openalex
- Steroid receptors in the uterus: implications in endometriosis via openalex
- W2163315477 via openalex
- W2016866851 via openalex
- W2104687197 via openalex
- W1569704074 via openalex
Cited by (20)
- Drospirenone promotes apoptosis in ectopic but inhibits proliferation in eutopic human endometrial stromal cells 2026
- Dienogest therapy: a window of opportunity for endometriosis 2023
- Hormonal Therapy in Endometriosis and Adenomyosis: Progestins 2022
- Endometriosis and adenomyosis: some aspects of medical (endocrine) treatment (part 1) 2022
- Colocalization of senescent biomarkers in deep, superficial, and ovarian endometriotic lesions: a pilot study 2022
- Endometriosis Research: From Bench to Bedside 2022
- Endometriosis 2020
- Evaluation of the ocular surface by impression cytology in patients with endometriosis 2020
- Hormonal contraceptives and endometriosis: modern view on the problem 2020
- A progestin isn't a progestin: dienogest for endometriosis as a blueprint for future research - Review as a contribution for discussion 2020
- The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights 2019
- A comprehensive review of hormonal and biological therapies for endometriosis: latest developments 2019
- Signal molecules involved in the formation of new nerve endings in endometriosis (review) 2019
- Exosome-mediated microRNA-138 and vascular endothelial growth factor in endometriosis through inflammation and apoptosis via the nuclear factor-κB signaling pathway 2018
- Progesterone Resistance in Endometriosis: an Acquired Property? 2018
- Comparison of dienogest effects upon 3,3'-diindolylmethane supplementation in models of endometriosis and clinical cases 2018
- Current and emerging treatment options for endometriosis 2018
- Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis 2018
- Predictive biomarkers may allow precision therapy of endometriosis 2017
- The Expression of Cyclophilin A in Ovarian Endometrioma: Its Correlation with Recurrence and Vascularity 2017
Source provenance
- europepmc
- last seen: 2026-10-09T06:09:53.026058+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:19:42.633400+00:00
License: CC0
· commercial use OK